Genovis AB (publ.) (GENO.ST)
Makes enzymes that help scientists develop new drugs and diagnostic tests.
19.92-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-25.3%
The outlook
Genovis sits well above its key moving averages with unanimous analyst "Strong Buy" ratings. The stock trades in the lower third of its 52-week range, and the average analyst price target sits about 61% above the current level. The overall sentiment leans decidedly bullish based on current data.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 3 analysts
Price trendAbove its 50- & 200-day averages
52-week range34% of the way from its 52-week low to high
Price targetAvg target +61% vs current price
Analyst price target
~12-month · 3 analysts32.00average target+60.6% vs now
Now 19.92
Low 28.00High 38.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.32B
52-wk high
28.20
52-wk low
15.64
50-day avg
19.51
200-day avg
19.82
Trailing P/E
64.3